Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025
Laura D. Zambrano
, Regina M. Simeone
, Margaret M. Newhams
, Amanda B. Payne
, Natasha B. Halasa
, Amber O. Orzel-Lockwood
, Jemima M. Calixte
, Satoshi Kamidani
, Hillary Crandall
, Melissa A. Cameron
, Jennifer E. Schuster
, Aline B. Maddux
, Kathleen Chiotos
, Katherine Irby
, Steven L. Shein
, Mary Allen Staat
, Lora M. Martin
, Samina S. Bhumbra
, Ryan A. Nofziger
, Jigar C. Chauhan
Danielle M. Zerr, Shira J. Gertz, Judith A. Guzman-Cottrill, Michele Kong, Janet R. Hume, Bria M. Coates, Kelly N. Michelson, Emily R. Levy, Tamara T. Bradford, Stephanie P. Schwartz, Tracie C. Walker, Melissa S. Stockwell, Austin Biggs, Alexander H. Hogan, Katherine Lindsey, Angela P. Campbell, Adrienne G. Randolph
Dive into the research topics of 'Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025'. Together they form a unique fingerprint.
Keyphrases
Medicine and Dentistry
Nursing and Health Professions
Pharmacology, Toxicology and Pharmaceutical Science